The new chemotherapy delivery system Gem-iDRS (Inlexzo) was designed to deliver sustained release of gemcitabine directly into the bladder for muscle-invasive bladder cancer. It was combined with systemic immunotherapy in the study treatment. The intravesical drug delivery system did not show the expected results. The study does not report specific efficacy statistics. The treatment was designed to improve the delivery of gemcitabine. The results did not meet the goals in this form of cancer.